MedTrace Logo

Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer

NCT01298011 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2015-06-17

No results posted yet for this study

Summary

The main purpose of this research study is to evaluate whether Abraxane and gemcitabine are effective in treating patients with operable pancreatic cancer.

Conditions

  • Resectable Pancreatic Cancer

Interventions

DRUG

Gemcitabine and Abraxane

3 treatments for gemcitabine and abraxane every 28-days for 3 months, prior to surgery.

Sponsors & Collaborators

  • Celgene Corporation

    collaborator INDUSTRY

  • Pancreatic Cancer Research Team

    lead OTHER

Principal Investigators

  • Ramesh K. Ramanathan, MD · TGen Drug Development

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2013-12-31
Completion
2015-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01298011 on ClinicalTrials.gov